AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31678224 — intervention group
Group type: EXPERIMENTAL
Intervention: Local consolidative therapy (LCT)
Number of subjects: 49
Study 31678224 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interleukin 1α
Number of subjects: 49
Study 31678224 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ctDNA analysis
Number of subjects: 49
Study 31369355 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Model (IBM)‐based 3‐month transitional care (TC) intervention
Number of subjects: 60
Study 31369355 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study 24858257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Chinese medicine (CM) and Western medicine intervention termed optimum proposal of integration of disease and syndrome (OPIDS)
Number of subjects: 126
Study 24858257 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 126
Study 23470610 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride with ECT
Number of subjects: 20
Study 23470610 — intervention group
Group type: COMPARATOR
Intervention: Control group (ECT without amisulpride)
Number of subjects: 20
Study 23470610 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (Amisulpride with ECT)
Number of subjects: 20
Study 21319927 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety behavior reduction plus exposure (SB + EXP)
Number of subjects: 80
Study 21319927 — intervention group
Group type: COMPARATOR
Intervention: Graduated exposure (EXP)
Number of subjects: 80
Study 19573229 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory return-to-work (RTW) program developed using the Intervention Mapping (IM) protocol.
Number of subjects: 0
Study 19573229 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying obstacles for RTW and formulating solutions for suitable (therapeutic) work with the help of an independent RTW coordinator.
Number of subjects: 0
Study 19573229 — intervention group
Group type: EXPERIMENTAL
Intervention: Assignment of a vocational rehabilitation agency to find a matching (therapeutic) workplace based on the RTW implementation plan.
Number of subjects: 0
Study 19573229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the participatory RTW program will be evaluated in a randomised controlled trial.
Number of subjects: 0
Study 16919054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) on the right and left cheeks and back of the hands
Number of subjects: 26
Study 16919054 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects performing QST
Number of subjects: 26
Study 15646911 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of local anesthetics, 2.5% lidocaine and 2.5% prilocaine) cream
Number of subjects: 31
Study 15646911 — intervention group
Group type: COMPARATOR
Intervention: Non-EMLA (placebo)
Number of subjects: 31
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: levormeloxifene 1.25 mg/day
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: levormeloxifene 5 mg/day
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: levormeloxifene 10 mg/day
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: levormeloxifene 20 mg/day
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose HRT (1 mg 17 beta‐estradiol and 0.5 mg norethisterone acetate/day)
Number of subjects: 301
Study 11158042 — intervention group
Group type: COMPARATOR
Intervention: placebo (500 mg calcium)
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: levormeloxifene
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose HRT
Number of subjects: 301
Study 11158042 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301
Study 11158042 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 301
Study 9764965 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 14
Study 9764965 — intervention group
Group type: COMPARATOR
Intervention: rac-bupivacaine
Number of subjects: 14
Study 7825466 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 0
Study 7825466 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-based formula without bovine lactoferrin, iron or nucleotides
Number of subjects: 0
Study 7825466 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding (general)
Number of subjects: 0
Study 3293762 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-matched single-donor platelet transfusions
Number of subjects: 78
Study 3293762 — intervention group
Group type: COMPARATOR
Intervention: Mismatched single-donor platelet transfusions
Number of subjects: 78
Study 29635632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5
Number of subjects: 71
Study 29635632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:8
Number of subjects: 71
Study 29635632 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 71
Study 26893030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (supine treadmill exercise within lower body negative pressure for 3-4 days/wk and flywheel resistive exercise for 2-3 days/wk)
Number of subjects: 16
Study 26893030 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 26893030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 16
Study 26893030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 25511551 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intravaginal 0.50% prasterone for 2 weeks followed by twice weekly for 10 weeks
Number of subjects: 0
Study 25511551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23229772 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory model
Number of subjects: 0
Study 23229772 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual model
Number of subjects: 0
Study 23229772 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory + visual model
Number of subjects: 0
Study 23229772 — intervention group
Group type: COMPARATOR
Intervention: Control (visual metronome)
Number of subjects: 0
Study 21524710 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana consumption (one medium banana twice a day)
Number of subjects: 34
Study 21524710 — intervention group
Group type: COMPARATOR
Intervention: Banana-flavoured drink (one cup twice a day)
Number of subjects: 34
Study 21524710 — intervention group
Group type: COMPARATOR
Intervention: Water (one cup twice a day)
Number of subjects: 34
Study 19505388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-co-seasonal sublingual immunotherapy with modified allergen extract
Number of subjects: 0
Study 19505388 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 16772806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Paracetamol 5/325 mg and 10/650 mg
Number of subjects: 30
Study 16772806 — intervention group
Group type: COMPARATOR
Intervention: Bromfenac 25 mg and 50 mg
Number of subjects: 30
Study 16772806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily (level 1)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily (level 1)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily (level 2)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily (level 2)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg added (level 3)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (Valsartan and Amlodipine)
Number of subjects: 164
Study 15531006 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sustained hypertension
Number of subjects: 164
Study 11513283 — intervention group
Group type: EXPERIMENTAL
Intervention: Various measures for assessing acute pain in infants; specific interventions not detailed.
Number of subjects: 0
Study 9279269 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-led physical education classes (40 min per week)
Number of subjects: 955
Study 9279269 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led physical education classes (33 min per week)
Number of subjects: 955
Study 9279269 — intervention group
Group type: COMPARATOR
Intervention: Control classes (18 min per week)
Number of subjects: 955
Study 9279269 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-led condition for girls
Number of subjects: 955
Study 8356997 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone (1,000‐2,000 mg/day)
Number of subjects: 1000
Study 8356997 — intervention group
Group type: COMPARATOR
Intervention: diclofenac (100‐200 mg/day)
Number of subjects: 1000
Study 8356997 — intervention group
Group type: COMPARATOR
Intervention: naproxen (500‐1,500 mg/day)
Number of subjects: 1000
Study 3064591 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 105
Study 3064591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 29091527 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-Based (CB) Exercise
Number of subjects: 172
Study 29091527 — intervention group
Group type: COMPARATOR
Intervention: Home-Based (HB) Exercise
Number of subjects: 172
Study 28851317 — intervention group
Group type: EXPERIMENTAL
Intervention: NaturaLyte® acid concentrate (4 mEq/L acetate)
Number of subjects: 11
Study 28851317 — intervention group
Group type: EXPERIMENTAL
Intervention: GranuFlo® acid concentrate (8 mEq/L acetate)
Number of subjects: 11
Study 28851317 — intervention group
Group type: COMPARATOR
Intervention: Both NaturaLyte® and GranuFlo®
Number of subjects: 11
Study 25498218 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy (four cycles of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC])
Number of subjects: 284
Study 25498218 — intervention group
Group type: COMPARATOR
Intervention: Deferred chemotherapy (six cycles at relapse)
Number of subjects: 284
Study 25498218 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy
Number of subjects: 284
Study 25498218 — intervention group
Group type: COMPARATOR
Intervention: Deferred chemotherapy
Number of subjects: 284
Study 23683266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g/d of omega-3 fatty acid (O3A) ethyl esters
Number of subjects: 48
Study 17038572 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation for 6 months
Number of subjects: 702
Study 17038572 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 702
Study 12839147 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 0
Study 12839147 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 500 mg 3 times daily for 10 days
Number of subjects: 0
Study 10435684 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 106
Study 10435684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam (sultamicillin)
Number of subjects: 106
Study 10435684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 106
Study 10435684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor monohydrate
Number of subjects: 106
Study 7848019 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative prophylaxis for VTE (specifics not provided)
Number of subjects: 0
Study 7848019 — intervention group
Group type: COMPARATOR
Intervention: Preoperative prophylaxis for VTE (specifics not provided)
Number of subjects: 0
Study 7848019 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily, low-molecular-weight heparin
Number of subjects: 0
Study 2248843 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and lignocaine
Number of subjects: 0
Study 2248843 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with adrenaline
Number of subjects: 0
Study 2248843 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 0
Study 7425697 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet supplemented with milk whey protein
Number of subjects: 18
Study 30422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 489
Study 30422193 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 489
Study 30422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative-hypnotics (intervention)
Number of subjects: 489
Study 30422193 — intervention group
Group type: COMPARATOR
Intervention: Sedative-hypnotics (control)
Number of subjects: 489
Study 30422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (intervention)
Number of subjects: 489
Study 30422193 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (control)
Number of subjects: 489
Study 30422193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (intervention)
Number of subjects: 489
Study 30422193 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (control)
Number of subjects: 489
Study 27375714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol
Number of subjects: 60
Study 27375714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 60
Study 27375714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol plus 0.5 mg/kg ketamine
Number of subjects: 60
Study 26242117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Shuji Granule (BSG)
Number of subjects: 62
Study 26242117 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib Capsule (Control)
Number of subjects: 62
Study 23768121 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric program
Number of subjects: 23
Study 23768121 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability program
Number of subjects: 23
Study 23768121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 20667337 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscle repositioning (PMR)
Number of subjects: 50
Study 20667337 — intervention group
Group type: COMPARATOR
Intervention: Total chordal-sparing mitral valve replacement
Number of subjects: 50
Study 18431218 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention (Ask and Advise + fax referral to quitline)
Number of subjects: 240
Study 15657341 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (37.5 Gy in 16 fractions)
Number of subjects: 318
Study 12558306 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam via ECMO circuit
Number of subjects: 20
Study 12558306 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 20
Study 10589645 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostat device (hypothermia warming mitt/seal and thermal exchange chamber for 60 min)
Number of subjects: 60
Study 10589645 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (warm blankets and/or radiant heat)
Number of subjects: 60
Study 7847521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gm daily intravenous)
Number of subjects: 178
Study 7847521 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 gm three times daily intravenous)
Number of subjects: 178
Study 1819436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined yellow‐fever‐measles vaccine
Number of subjects: 453
Study 1819436 — intervention group
Group type: COMPARATOR
Intervention: Yellow‐fever and measles separate administration
Number of subjects: 453
Study 7199334 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam maleate
Number of subjects: 30
Study 7199334 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 7199334 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30
Study 31877392 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant carrying (babywearing) for 1 hour daily for 3 months
Number of subjects: 33
Study 31877392 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading)
Number of subjects: 33
Study 30758327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 25
Study 30758327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28466151 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted interventions including local quality improvement teams, educational outreach, audit, feedback, and reminders.
Number of subjects: 4183
Study 28466151 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous medical education (CME) measures.
Number of subjects: 4183
Study 28466151 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in antimicrobial therapy.
Number of subjects: 4183
Study 28466151 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in source control.
Number of subjects: 4183
Study 26503395 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational intervention for carers (4 components: initial telephone assessment, tailored resource folder, home visit, ongoing monthly support for 12 months)
Number of subjects: 240
Study 26503395 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study 23813851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme (four outpatient nurse clinic visits focusing on healthy lifestyles, biometric risk factors, and medication adherence)
Number of subjects: 754
Study 23813851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated prevention programme
Number of subjects: 754
Study 23813851 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 754
Study 22118755 — intervention group
Group type: EXPERIMENTAL
Intervention: Longevinex administered for 3 months (Group A)
Number of subjects: 34
Study 22118755 — intervention group
Group type: EXPERIMENTAL
Intervention: Longevinex administered between 3 and 6 months (Group B)
Number of subjects: 34
Study 22118755 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 34
Study 19302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg BID for 7 days
Number of subjects: 12
Study 19302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg BID for 7 days
Number of subjects: 12
Study 19302901 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 400 mg once daily for 7 days
Number of subjects: 12
Study 19302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (oral 2 mg and IV 0.4 mg) administered with either azole
Number of subjects: 12
Study 19302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported with posaconazole alone
Number of subjects: 12
Study 19302901 — intervention group
Group type: COMPARATOR
Intervention: Adverse events reported with ketoconazole alone
Number of subjects: 12
Study 19302901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported with posaconazole + midazolam
Number of subjects: 12
Study 17582178 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day in two divided doses)
Number of subjects: 51
Study 17582178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized steroids (Budecort 50 mcg/dose twice daily)
Number of subjects: 51
Study 17582178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 51
Study 17582178 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 51
Study 15449752 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of 6% hydroxyethylstarch (HES)
Number of subjects: 75
Study 15449752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml of 6% hydroxyethylstarch (HES)
Number of subjects: 75
Study 15449752 — intervention group
Group type: COMPARATOR
Intervention: No preload (Control)
Number of subjects: 75
Study 11343734 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by primary-care physician
Number of subjects: 988
Study 11343734 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by pain specialist
Number of subjects: 988
Study 11343734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience of pain
Number of subjects: 988
Study 11343734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall desire for additional treatment
Number of subjects: 988
Study 11343734 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics
Number of subjects: 988
Study 9518909 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam 10 mg
Number of subjects: 11
Study 9518909 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 7853442 — intervention group
Group type: EXPERIMENTAL
Intervention: Manioc Salt Solution (MSS)
Number of subjects: 333
Study 7853442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap Salt Solution (PSS)
Number of subjects: 333
Study 7853442 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization/Oral Rehydration Solution (WHO/ORS)
Number of subjects: 333
Study 2768761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 6
Study 2768761 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 6
Study 189333 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ACTH 4-10 subcutaneously
Number of subjects: 0
Study 189333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Care received in Rwanda (intervention group)
Number of subjects: 1413